ClinicalTrials.gg
CompletedNCT06988553Updated Dec 23, 2025

A Phase Ib Study of AZD5004 in Chinese Participants With Overweight/Obesity With or Without Type 2 Diabetes Mellitus

A Phase 1 interventional study of AZD5004 and Placebo in Obesity or Overweight and Type 2 Diabetes, sponsored by Eccogene. Completed at 6 sites in China. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Eccogene · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 601 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.

Enrollment
406th of 503
45 · median 120
Started
2025
with 113 others
Phase 1
93 of 601
29 open now
Registered
364th of 601
by date

Among the 601 studies in Obesity with a site in China, this one is the 406th largest by enrollment of the 503 interventional ones that give a count, is one of 114 that started in 2025, is one of 93 in phase 1, and was the 364th registered.

Obesity

11,547 studies on the registry are indexed under Obesity; 2,050 are open to participants now.

Browse Obesity studies →

Open to participants now

221 of the 601 studies in Obesity with a site in China are open now. Recruiting first, the newest first:

216 more — sign in →

All 221 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,343 Obesity studies recruiting now, 377 (28%) set no upper age limit and 862 (64%) stop at 75 or younger; 168 take children under 18; 488 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 601 studies in Obesity with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese participants with overweight/obesity with or without T2DM.

Read the detailed description

This is a Phase Ib, randomized, parallel-group, double-blind, placebo-controlled, multicentre, 2-arm treatment study to investigate the safety, tolerability, and PK of AZD5004 compared with placebo in Chinese male and female participants aged 18 to 74 years, who are overweight/obese with or without T2DM. The primary endpoints are incidence of AEs, SAEs, DAEs, death, AESIs, laboratory parameters, 12-lead ECG, and vital signs.

03

Conditions studied

  • Obesity or Overweight
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Aged 18 to 74 years inclusive at the time of signing the .
  • Stable self-reported body weight for 3 months prior to Screening.

Inclusion Criteria for Cohort A:

- 27 kg/m2 ≤ ≤ 35 kg/m2 and weigh at least 60 kg at Screening.

Inclusion Criteria for Cohort B:

  • Diagnosed with T2DM for at least 6 months prior to signing the informed consent.
  • value at Screening of ≥ 7.0% and ≤ 10.5%
  • BMI of ≥ 24 kg/m2 at the Screening Visit.

Exclusion Criteria:

  • History of, or any existing condition that influence the participant's ability to participate or affect the interpretation of the results of the study.
  • Known gastric emptying abnormality.
  • Significant hepatic disease.
  • Abnormal renal function.
  • History of acute pancreatitis and chronic pancreatitis, gallstones.
  • Uncontrolled thyroid disease.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    AZD5004

    Participants will receive AZD5004 orally.

    Drug: AZD5004

  • Placebo comparator
    Placebo

    Participants will receive Placebo orally.

    Drug: Placebo

Interventions

  • AZD5004 will be administered as an oral tablet once daily.

  • DrugPlacebo

    Placebo will be administered as an oral tablet once daily.

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse event leading to the discontinuation of study intervention (DAEs), death, and Adverse events of special interest (AESIs)

    To evaluate the safety and tolerability of AZD5004 compared with placebo.

    Time frame: From baseline to week 16.

Secondary outcomes

  1. AZD5004 concentrations in plasma

    To characterize the PK profile of AZD5004 following repeated administration.

    Time frame: Week 16.

  2. Area under the concentration-time curve over a dosing interval (AUCtau)

    To characterize the PK profile of AZD5004 following repeated administration.

    Time frame: Week 16.

  3. Maximum Observed Plasma Concentration (Cmax)

    To characterize the PK profile of AZD5004 following repeated administration.

    Time frame: Week 16.

  4. Half-Life (t1/2)

    To characterize the PK profile of AZD5004 following repeated administration.

    Time frame: Week 16.

  5. Time of Occurrence of Maximum Plasma Concentration (tmax)

    To characterize the PK profile of AZD5004 following repeated administration.

    Time frame: Week 16.

  6. Trough concentration (Ctrough)

    To characterize the PK profile of AZD5004 following repeated administration.

    Time frame: Week 16.

07

Study locations

6 sites
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Ha’erbin, China
  • The Second People's Hospital of Hefei
    Hefei, China
  • Jinan Central Hospital
    Jinan, China
  • Shanghai Pudong New District People's Hospital
    Shanghai, China
  • General Hospital of Tianjin Medical University
    Tianjin, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Nov 2025, 5 months.

Of 336 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 5 months is below that.

Counting every sponsor, half of 441 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
May 25, 2025
StartActual
Jun 17, 2025
Primary completionActual
Nov 28, 2025
CompletionActual
Nov 28, 2025
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06988553
Lead sponsor
Eccogene
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Jun 17, 2025
Primary completion
Nov 28, 2025
Completion
Nov 28, 2025
Last update
Dec 23, 2025

Study contacts

Eccogene
study director · Eccogene Clinical Trials

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Elecoglipron

Start the discussion